ArticleInflammatory bowel diseases2022

Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease: Results from a Phase 1 Randomized Trial.

Wenhui Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.